Long-term safety and efficacy of the selective aldosterone blocker eplerenone in patients with essential hypertension
- 1 September 2003
- journal article
- clinical trial
- Published by Elsevier in Clinical Therapeutics
- Vol. 25 (9) , 2388-2404
- https://doi.org/10.1016/s0149-2918(03)80282-5
Abstract
No abstract availableKeywords
This publication has 24 references indexed in Scilit:
- Aldosterone in Congestive Heart FailureNew England Journal of Medicine, 2001
- MINERALOCORTICOIDS AND CARDIAC FIBROSIS: THE DECADE IN REVIEWClinical and Experimental Pharmacology and Physiology, 2001
- Eplerenone: A Selective Aldosterone Receptor Antagonist (SARA)Cardiovascular Drug Reviews, 2001
- Aldosterone as a mediator of progressive renal disease: Pathogenetic and clinical implicationsAmerican Journal of Kidney Diseases, 2001
- Arterial Pressure, Left Ventricular Mass, and Aldosterone in Essential HypertensionHypertension, 2001
- Aldosterone Production Is Activated in Failing Ventricle in HumansCirculation, 2001
- Aldosterone: A Mediator of Myocardial Necrosis and Renal ArteriopathyEndocrinology, 2000
- Cardiovascular complications in patients with primary aldosteronismAmerican Journal of Kidney Diseases, 1999
- Changes in Left Ventricular Anatomy and Function in Hypertension and Primary AldosteronismHypertension, 1996
- Hormones regulating cardiovascular function in patients with severe congestive heart failure and their relation to mortality. CONSENSUS Trial Study Group.Circulation, 1990